- Do you, or did you, own shares of Zafgen, Inc. (NASDAQ: ZFGN)?
- Did you purchase your shares between January 12, 2015 and October 16, 2015?
- Did you lose money in your investment?
Please contact Rigrodsky & Long, P.A. (“R & L”) to schedule a free consultation. You may call us or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.
R & L is investigating claims brought in a securities fraud class action complaint against Zafgen, Inc. ("Zafgen") concerning whether Zafgen and certain of the Company’s directors and/or officers made materially false and misleading statements and failed to disclose materially adverse facts during the period January 12, 2015 and October 16, 2015 (the “Class Period”), concerning adverse thrombotic events experienced by patients in the Company’s clinical trials of its primary new drug product, beloranib. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.